Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTX001 in Liver Cirrhosis with Hepatic Decompensation
NCT06823713Phase 2Active, not recruiting
- Sponsor
- Resolution Therapeutics
- Start
- Oct 2024
- Primary completion
- Aug 2028
- Modality
- CAR-Macrophages
- Countries
- 2
01
Overview
A Phase 2 trial of RTX001 in Liver cirrhosis (LC), liver disease, sponsored by Resolution Therapeutics. Started Oct 2024; status: active, not recruiting.
02
Drugs
RTX001
03
Conditions
Liver cirrhosis (LC)liver disease
Beyond the preview
Go deeper on NCT06823713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823713.